This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Surgical Oncology  • Computed Tomography  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

David B. Adams, MD

Arch Surg. 2008;143(3):281.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 1972, when asked about the lasting effects of the French Revolution, Zhou Enlai replied, "Too soon to tell."¹ The same answer is given when questions arise about the value of updated radiologic imaging in staging and managing pancreatic cancer. Consider, for example, the year 1977. In July, Creditor and Garrett² reported in The New England Journal of Medicine about how the innovations of CT were being introduced into clinical practice. They decried that expensive technologies were widely adopted without evidence of clinical utility. In an era when more than 40% of Blue Cross plans did not reimburse for whole-body scanning, evidence for the efficacy of CT scanning was missing.³ What was clear in 1977, however, was that current diagnostic tests for pancreatic cancer were of limited utility. Abdominal ultrasonography, pancreatic function tests, ERCP, and arteriography were the sequence of tests recommended in a prospective study . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Treatment Decision Making in Pancreatic Adenocarcinoma: Multidisciplinary Team Discussion With Multidetector-Row Computed Tomography
Hiroyoshi Furukawa, Katsuhiko Uesaka, and Narikazu Boku
Arch Surg. 2008;143(3):275-280.
ABSTRACT | FULL TEXT